January 17, 2025 Regulatory AcuCort’s Chairman subscribes for an additional approximately SEK 200,000 in the ongoing rights issue
January 14, 2025 Regulatory AcuCort’s CEO subscribes for an additional SEK 1 million in the ongoing rights issue, bringing total commitment to approximately SEK 2 million
March 11, 2024 Regulatory Insider trading in subscription option TO1 – CEO Jonas Jönmark increases his stake in AcuCort AB
November 30, 2023 Regulatory AcuCort publishes the Interim Report for the third quarter 2023 (in Swedish)
August 31, 2023 Regulatory AcuCort signs partnership agreement for the four major Nordic countries with Unimedic Pharma
April 28, 2023 Regulatory AcuCort publishes the Interim Report for the first quarter 2023 (in Swedish)
February 20, 2023 Regulatory The FDA is requesting additional information prior to AcuCort’s registration application in the United States
January 24, 2023 Regulatory AcuCort receives market approval from the Finnish Medicines Agency for the drug Zeqmelit®
November 23, 2022 Regulatory AcuCort signs its first commercial agreement for the company’s drug Zeqmelit™
November 11, 2022 Regulatory AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
October 19, 2022 Regulatory AcuCort receives a granted patent in Canada for the company’s drug Zeqmelit™
September 27, 2022 Regulatory AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency
August 16, 2022 Regulatory AcuCort receives marketing authorization for the drug Zeqmelit by the Danish Medicines Agency
August 12, 2022 Regulatory AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)
June 8, 2022 Regulatory AcuCort’s application for ethical review for a questionnaire study on allergy treatment is approved
April 28, 2022 Regulatory AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)
April 26, 2022 Regulatory AcuCort applies for ethical review for a questionnaire study on allergy treatment
March 1, 2022 Regulatory AcuCort is exempted from the application fee by the U.S. Food and Drug Administration
February 22, 2022 Regulatory AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT®
February 17, 2022 Regulatory AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®
November 15, 2021 Regulatory AcuCort announces that the registration process in the Nordic market is underway for the company’s drug ISICORT®
August 11, 2021 Regulatory AcuCort announces that the Board of Directors and the CEO have subscribed for options to purchase shares in the company
April 26, 2021 Regulatory AcuCort progresses into a new phase and strengthens the commercialization team
October 7, 2020 Regulatory AcuCort receives market approval from the Swedish Medical Products Agency for the drug ISICORT®
May 28, 2020 Regulatory AcuCort comments on the status update regarding the second US patent application
March 17, 2020 Regulatory AcuCort AB: Correction, missing MAR label in the press release on March 16, 2020
February 13, 2020 Regulatory AcuCort confirms response from the Swedish MPA regarding ISICORT® market application
November 8, 2019 Regulatory AcuCort gives an update on the continued work concerning the bioequivalence study for US registration
October 16, 2019 Regulatory AcuCort reports that bioequivalence was not achieved in the second study for US registration
January 23, 2019 Regulatory AcuCort obtains regulatory approval to start bioequivalence study for the US
October 4, 2018 Regulatory AcuCort obtains regulatory approval to start bioequivalence study for the EU
September 7, 2018 Regulatory AcuCort’s allergy medicine Dexa ODF has been manufactured and released according to Good Manufacturing Practice, GMP
June 21, 2018 Regulatory AcuCort signs agreement with the CRO Quinta-Analytica concerning the performance of bioequivalence studies
June 12, 2018 Regulatory AcuCort’s allergy treatment Dexa ODF is ready to be manufactured according to GMP (Good Manufacturing Practice) for clinical use
April 24, 2018 Regulatory Correction and clarification concerning the expiry dates of AcuCort’s patents
April 16, 2018 Regulatory AcuCort’s patent is granted with 1,349 days extended patent protection in the US